GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » EV-to-FCF

Telix Pharmaceuticals (Telix Pharmaceuticals) EV-to-FCF : 377.76 (As of May. 12, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Telix Pharmaceuticals's Enterprise Value is $3,317.1 Mil. Telix Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $8.8 Mil. Therefore, Telix Pharmaceuticals's EV-to-FCF for today is 377.76.

The historical rank and industry rank for Telix Pharmaceuticals's EV-to-FCF or its related term are showing as below:

TLPPF' s EV-to-FCF Range Over the Past 10 Years
Min: -45.94   Med: -13.78   Max: 1205.56
Current: 382.96

During the past 9 years, the highest EV-to-FCF of Telix Pharmaceuticals was 1205.56. The lowest was -45.94. And the median was -13.78.

TLPPF's EV-to-FCF is ranked worse than
95.38% of 390 companies
in the Biotechnology industry
Industry Median: 6.365 vs TLPPF: 382.96

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Telix Pharmaceuticals's stock price is $10.20. Telix Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.011. Therefore, Telix Pharmaceuticals's PE Ratio for today is 927.27.


Telix Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Telix Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals EV-to-FCF Chart

Telix Pharmaceuticals Annual Data
Trend Sep99 Sep00 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -14.71 600.85 -36.10 -28.19 241.21

Telix Pharmaceuticals Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.10 - -28.19 - 241.21

Competitive Comparison of Telix Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, Telix Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telix Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Telix Pharmaceuticals's EV-to-FCF falls into.



Telix Pharmaceuticals EV-to-FCF Calculation

Telix Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=3317.081/8.781
=377.76

Telix Pharmaceuticals's current Enterprise Value is $3,317.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Telix Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $8.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telix Pharmaceuticals  (OTCPK:TLPPF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Telix Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=10.20/0.011
=927.27

Telix Pharmaceuticals's share price for today is $10.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Telix Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.011.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Telix Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Telix Pharmaceuticals (Telix Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.